Pneumococcusprevenció a kora csecsemokortól az idoskorig

Orvosi Hetilap

Volumn 155, Issue 7, 2014, Pages 243-247

  Mészner, Zsófia ^a  

^a Gyermekegészségügyi Intézet ^*  (Hungary)

Author keywords

herd immunity; Pneumococcus; polysaccharide vaccines; polysaccharide conjugate vaccines; Streptococcus pneumoniae

Indexed keywords

HERD IMMUNITY; KONJUGÁLTPOLISZACHARID-VAKCINA; NYÁJIMMUNITÁS; PNEUMOCOCCUS; POLISZACHARIDVAKCINA; POLYSACCHARIDE VACCINES; POLYSACCHARIDE-CONJUGATE VACCINES; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; HUMANS; HUNGARY; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; INFLUENZA, HUMAN; MENINGITIS, PNEUMOCOCCAL; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; WORLD HEALTH;

EID: 84894222401     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2014.29753     Document Type: Article

References (29)

1. http://www.who.int/nuvi/pneumococcus/en/"http://www.who.int/nuvi/ pneumococcus/en/
2. Gladstone, R. A., Jefferies, J. M., Faust, S. N., et al.: Continued control of pneumococcal disease in the UK-the impact of vaccination. J. Med. Microbiol., 2011, 60, 1-8.
3. Long, S. S., Pickering, L. K., Prober, C. G. (eds.): Principles and practice of pediatric infectious diseases. 3rd ed. Churchill Livingstone, New York, 2008.
4. Bogaert, D., De Groot, R., Hermanns, P. W.: Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect. Dis., 2004, 4, 144-154. (Pubitemid 38293138)
5. Aniansson, G., Alm, B., Andersson, B., et al.: Nasopharyngeal colonization during the first year of life. J. Infect. Dis., 1992, 165 (Suppl. 1), S38-S42.
6. http://www.ecdc.europa.eu/en/healthtopics/pneumococcal-infection/ basic-facts"http://www.ecdc.europa.eu/en/healthtopics/pneumococcal- infection/basic-facts . [Accessed: October 2011]
7. Cohen, R., Levy, C., Bingen, E., et al.: Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr. Infect. Dis. J., 2012, 31, 297-301.
8. http://ecdc.europa.eu/en/publications/Publications/invasive-pneumoccocal- disease-surveillance-2010.pdf"http://ecdc.europa.eu/en/publications/ Publications/invasive-pneumoccocal-disease-surveillance-2010.pdf
9. Mészner, Zs., Füzi, M.: Prospective evaluation of the incidence of IPD (invasive pneumococcal disease), the serotypes and rezistance of Streptococcus pneumoniae isolates in hospitalised Hungarian children 5y. Two year observational study. In: 23rd Annual ESPID Meeting, Valencia (Spain). Book of abstracts, 2005. http://meetings.espid.org/espid2005/program/searchresults. asp"http://meetings.espid.org/espid2005/program/searchresults.asp
10. Clutterbuck, E. A., Lazarus, R., Yu, L. M., et al.: Pneumococcal conjugate and plain plysaccharide vaccines have divergent effects on antigen-specific B cells. J. Infect. Dis., 2012, 205, 1408-1416.
11. WHO: Pneumococcal vaccines. WHO position paper-2012. Weekly Epidemiological Record, 2012, 87, 129-144. http://www.who.int/wer"http:// www.who.int/wer
12. CDC: Use of 23-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly Rep., 2013, 62, 521-524.
13. CDC: Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly Rep., 2012, 61, 816-819.
14. Blasi, F., Mantero, M., Santus, P., et al.: Understanding the burden of pneumococcal disease in adults. Clin. Microbiol. Infect., 2012, 18 (Suppl. 5), 7-14.
15. Kaplan, S. L., Barson, W. J., Lin, P. L., et al.: Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J., 2013, 32, 203-207.
16. Gruber, W. C., Scott, D. A., Emini, E. A.: Development and clinical evaluation of Prevnar 13, a 13-valent pneumococcal CRMsub197/sub conjugate vaccine. Ann. N.Y. Acad. Sci., 2012, 1263, 15-26.
17. Miller, E., Andrews, N. J., Waight, P. A., et al.: Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine, 2011, 29, 9127-9131.
18. Hortal, M., Estevan, M., Laurani, H., et al.: Hospitalized children with pneumonia in Uruguay: Pre and post introduction of 7 and 13-valent pneumococcal conjugated vaccines into the National Immunization Program. Vaccine, 2012, 30, 4934-4938.
19. Singleton, R., Wenger, J., Klejka, J. A., et al.: The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Pediatr. Infect. Dis. J., 2013, 32, 257-263.
20. Muhammad, R. D., Oza-Frank, R., Zell, E., et al.: Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin. Infect. Dis., 2013, 56, e59-e67.
21. Paradiso, P. R.: Pneumococcal conjugate vaccine for adults: A new paradigm. Clin. Infect. Dis., 2012, 55, 259-264.
22. Sanford, M.: Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) in older adults. Drugs, 2012, 72, 1243-1255.
23. Lode, H., Ludwig, E., Kassianos, G.: Pneumococcal infection-Low awareness as a potential barrier to vaccination: Results of a European survey. Adv. Ther., 2013, 30, 387-405.
24. Tirczka, T., Berta, B.: The results of pneumococcal serotyping and rezisistance from January 1, 2008 to August 31, 2012. [A Streptococcus pneumoniae szerotipizálás és rezisztencia vizsgálat eredményei 2008.01.01-t?l 2012.08.31-ig.]. Mikrobiológiai körlevél, 2012, 12, 3-17. [Hungarian]
25. Tóthpál, A., Dobay, O.: Drastic changes in serotypes of carried pneumococci due to an increased vaccination rate in Hungary. [A hordozott pneumococcusok szerotípusainak drasztikus változá sa a megnövekedett átoltottság hatására hazánkban.] Orv. Hetil., 2012, 153, 1031-1034. [Hungarian]
26. The present state and results of the pneumococcal surveillance in Hungary, October 2012. [A pneumococcus surveillance jelenlegi helyzete és eredményei, Magyarország, 2012. október.]. Országos Epidemiológiai Központ, Epinfo 2012, 19 (45):521-528. [Hungarian]
27. Tóthpál, A., Laub, K., Kardos, Sz., et al.: Changes in the serotypes of Hungarian pneumococci isolated mainly from invasive infections: A review of all available data between 1988 and 2011. Acta Microbiol. Immunol. Hung., 2012, 59, 423-433.
28. Ludwig, E., Bonanni, P., Rohde, G., et al.: The remaining challenges of pneumococcal disease in adults. Eur. Respir. Rev., 2012, 21, 57-65.
29. Johnson, H. L., Deloria-Knoll, M., Levine, O. S., et al.: Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: The Pneumococcal Global Serotype Project. PLoS Med., 2010, 7, e1000348.